# Els Hubloux

> Els Hubloux is a seed investor at Newton Biocapital (Brussels) backing Biotechnology and Medical. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Newton Biocapital](https://shizune.co/investors/profile/newton-biocapital)
- Location: Brussels, Belgium
- Total investments: 3
- Last investment: Jan 2023
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/els-hubloux-34aa394/

Els Hubloux is a seed investor at Newton Biocapital in Brussels focused on Biotechnology and Medical. Els Hubloux - Partner @ Newton Biocapital

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Health Care | 1 | 33% |
| Manufacturing | 1 | 33% |
| Medical Device | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series A | 1 | 33% |
| Series B | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 1 | 33% |
| Switzerland | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| DeuterOncology | DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies. | $6.1M | Series A | Jan 19, 2023 |  |
| DeuterOncology | DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies. |  | Seed | Feb 24, 2021 |  |
| Sequana Medical | Sequana Medical is a Swiss medical device company providing implantable pump systems to manage fluid balance within the body. This system is designed to move excess fluid to the bladder, where it is passed naturally from the body through normal urination.Sequana Medical’s first product, the Alfapump System, is an innovative solution for themanagement of ascites. Ascites is a fluid that collects in the abdominal cavity in people with advanced liver disease, certain cancers, or congestive heart failure. Alfapump System was the first and only system for the automatic and continual removal of ascites.Sequana Medical was founded in 2006 and is based in Zurich, Switzerland. | $27.6M | Series B | Mar 09, 2011 |  |

3 of 3 investments shown.

## Co-investors
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 1 deal together
- [Entrepreneurs Fund](https://shizune.co/investors/profile/entrepreneurs-fund) — VC Fund, 1 deal together
- [Investsud](https://shizune.co/investors/profile/investsud) — VC Fund, 1 deal together
- [Meusinvest (Noshaq)](https://shizune.co/investors/profile/meusinvest) — VC Fund, 1 deal together
- [Noshaq](https://shizune.co/investors/profile/noshaq) — VC Fund, 1 deal together
- [VI Partners](https://shizune.co/investors/profile/vi-partners) — VC Fund, 1 deal together

## About Newton Biocapital

VC Fund · Brussels, Belgium

Newton Biocapital is a Venture Capital Fund incorporated in Belgium, focused on financing biotech and life science projects in the "core of Europe" (B, NL, D, F) and Japan for the prevention and treatment of chronic diseases.Their approach as lead investor is to support promising start-up projects as well as neglected or undervaluedlate-stage projects, in order to mitigate the risks and to create investor value. The leadership team consi.sts of specialists with long-standing management and investor experience who coach bio-entrepreneurs through the development stages of their projects.

4 contacts available at Newton Biocapital.

| Name | Title | Profile |
| --- | --- | --- |
| Els Hubloux | Partner | https://shizune.co/investors/profile/els-hubloux |
| Goro Takeda | Managing Partner | https://shizune.co/investors/profile/goro-takeda |
| Toshiyuki Mori | Partner, Tokyo | https://shizune.co/investors/profile/toshiyuki-mori |
| Alain Parthoens | Managing Partner and Founder | https://shizune.co/investors/profile/alain-parthoens |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Els Hubloux invest in?

Els Hubloux invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Els Hubloux last invest?

The most recent investment recorded for Els Hubloux closed in Jan 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co